NFKB1 and B-cell non-Hodgkin lymphoma: Oncogenic mutations in the TP53 protein are reported to be associated with higher RelA expression, in turn activating the canonical NF-κB pathway in human B-cell lymphomas such as Hodgkin lymphoma and, to a lesser extent in T-cell lymphoma cell lines as well [151,152].